Compare Akamai Technologies, Inc. (AKAM) vs BridgeBio Pharma Inc (BBIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Akamai Technologies, Inc. vs BridgeBio Pharma Inc — how do they compare? Akamai Technologies, Inc. trades at $116.57 (market cap $16.77B), while BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B). The key difference: Akamai Technologies, Inc. and BridgeBio Pharma Inc are close in size by market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Akamai Technologies, Inc. nearer its low. Which is the better fit depends on your goals.
| AKAM | BBIO | |
|---|---|---|
Market Cap | $16.77B | $16.36B |
Sector | Technology | Health |
52-Week High | $161.14 | $90.17 |
52-Week Low | $71.97 | $47.29 |
Enterprise Value | $22.75B | $18.14B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Akamai Technologies, Inc.
Akamai operates a content delivery network, or CDN, which entails locating servers at the edges of networks so its customers, which store content on Akamai servers, can reach their own customers faster, more securely, and with better quality. Akamai has over 325,000 servers distributed over 4,000 points of presence in more than 1,000 cities worldwide. Its customers generally include media companies, which stream video content or make video games available for download, and other enterprises that run interactive or high-traffic websites, such as e-commerce firms and financial institutions. Akamai also has a significant security business, which is integrated with its core web and media businesses to protect its customers from cyberthreats.
Read more on AKAM →About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →
